Increased cerbrospinal fluid cortisol and corticotropin releasing factor
President and Chief Executive Officer of Neurogen, said, "The combination of Neurogen's novel corticotrophin releasing factor
chemotype, the substantial quantity of promising chemical leads from our Accelerated Intelligent Drug Discovery system, and Aventis' impressive development and commercial expertise comprise all the right elements for a successful effort.
Reporting in the Proceedings of the National Academy of Sciences (PNAS), the scientists found that the gene, known as the corticotrophin releasing factor
(CRF) gene, is an important part of how humans respond to everyday stress, reports The BBC.
Investors may have been encouraged by this announcement because Theratechnologies is presently recruiting patients in a Phase 3 clinical trial for a similar indication testing its growth hormone releasing factor
analogue, TH9507, with results expected in the fourth quarter of 2006".
NTI is also developing XERECEPT(TM), a synthetic preparation of the natural peptide, Corticotropin Releasing Factor
(CRF), as a treatment for peritumoral brain edema.
15 /PRNewswire/ -- Researchers in the Laboratory of Structural Sciences at Van Andel Institute (VAI) have determined how the hormone corticotrophin releasing factor
(CRF) precisely binds to its receptor.
During the latter part of fiscal 2002, NTI moved ahead on the development of Xerecept, its corticotropin releasing factor
compound for peritumoral brain swelling.
announced today that its partner GlaxoSmithKline (GSK) has initiated a Phase I clinical trial with a lead Corticotropin Releasing Factor
1 (CRF1) receptor antagonist compound.
The LHRH agonist, a Roberts therapeutic, is a synthetic gonadotropic hormone releasing factor
agonist that, due to its long-term inhibition of pituitary release of gonadotropins, can block both ovarian and testicular function.
ThGRF is Theratechnologies' growth hormone releasing factor
analogue, which is slated to enter late-stage development for HIV-associated lipodystrophy in 2005.
Nasdaq: NBIX), announced today that they have entered into a collaborative agreement to discover and develop corticotropin releasing factor
(CRF)-binding protein ligand inhibitors for the treatment of at least two critical central-nervous-system disorders, obesity and dementia, such as that associated with Alzheimer's disease.
It is actually a growth therapy and it works on the principle that there are new growth releasing factors
that will help in rejuvenation and even regrowth of hair if it is used along with other holistic things like good diet, healthy lifestyle etc.